Edmund Harrigan Incyte Corp (INCY) insider trading activity

Edmund Harrigan is Director of INCYTE CORP. Currently has a direct ownership of 16,732 shares of INCY, which is worth approximately $1.23 Million. The most recent transaction as insider was on Sep 30, 2024, when has been sold 378 shares (Common Stock) at a price of $66.1 per share, resulting in proceeds of $24,985. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 16.7K

2.31% 3M change

36.27% 12M change

Total Value Held $1.23 Million

EDMUND HARRIGAN Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 30 2024	BUY Grant, award, or other acquisition	$24,985 $66.1 p/Share	378 Added 2.21%	16,732 Common Stock
Jun 28 2024	BUY Grant, award, or other acquisition	$24,793 $60.62 p/Share	409 Added 2.44%	16,354 Common Stock
Jun 12 2024	BUY Grant, award, or other acquisition	-	2,830 Added 15.07%	15,945 Common Stock
Mar 28 2024	BUY Grant, award, or other acquisition	$23,528 $56.97 p/Share	413 Added 3.05%	13,115 Common Stock
Dec 29 2023	BUY Grant, award, or other acquisition	$26,560 $62.79 p/Share	423 Added 3.22%	12,702 Common Stock
Sep 29 2023	BUY Grant, award, or other acquisition	$22,472 $57.77 p/Share	389 Added 3.07%	12,279 Common Stock
Jun 30 2023	BUY Grant, award, or other acquisition	$24,277 $62.25 p/Share	390 Added 3.18%	11,890 Common Stock
Jun 14 2023	BUY Grant, award, or other acquisition	-	2,505 Added 17.89%	11,500 Common Stock
Mar 31 2023	BUY Grant, award, or other acquisition	$23,560 $72.27 p/Share	326 Added 3.5%	8,995 Common Stock
Dec 30 2022	BUY Grant, award, or other acquisition	$24,256 $80.32 p/Share	302 Added 3.37%	8,669 Common Stock
Oct 19 2022	BUY Grant, award, or other acquisition	$11,482 $69.59 p/Share	165 Added 1.93%	8,367 Common Stock
Sep 30 2022	BUY Grant, award, or other acquisition	$16,660 $66.64 p/Share	250 Added 2.96%	8,202 Common Stock
Jun 30 2022	BUY Grant, award, or other acquisition	$17,929 $75.97 p/Share	236 Added 2.88%	7,952 Common Stock
Jun 15 2022	BUY Grant, award, or other acquisition	-	2,144 Added 21.74%	7,716 Common Stock
Mar 31 2022	BUY Grant, award, or other acquisition	$19,061 $79.42 p/Share	240 Added 4.13%	5,572 Common Stock
Dec 31 2021	BUY Grant, award, or other acquisition	$18,570 $73.4 p/Share	253 Added 4.53%	5,332 Common Stock
Sep 30 2021	BUY Grant, award, or other acquisition	$16,301 $68.78 p/Share	237 Added 4.46%	5,079 Common Stock
Jun 30 2021	BUY Grant, award, or other acquisition	$17,499 $84.13 p/Share	208 Added 4.12%	4,842 Common Stock
May 26 2021	BUY Grant, award, or other acquisition	-	1,923 Added 29.33%	4,634 Common Stock
Mar 31 2021	BUY Grant, award, or other acquisition	$17,798 $81.27 p/Share	219 Added 7.47%	2,711 Common Stock
Dec 31 2020	BUY Grant, award, or other acquisition	$18,005 $86.98 p/Share	207 Added 7.67%	2,492 Common Stock
Sep 30 2020	BUY Grant, award, or other acquisition	$16,781 $89.74 p/Share	187 Added 7.56%	2,285 Common Stock

Also insider at

PHAS

PhaseBio Pharmaceuticals Inc Healthcare

Director

ACAD

ACADIA PHARMACEUTICALS INC Healthcare

Edmund Harrigan

Director

Wilmington, DE

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells INCY shares.

Notify only if

Value

Insider Trading

Get notified when an Incyte Corp insider buys or sells INCY shares.

Notify only if

Operation

Value

Type

News

Receive news related to INCYTE CORP

Track Activities on INCY

Account